Cencora to Acquire American Oncology Network in $2.4 Billion Community Oncology Deal
Cencora Inc., the pharmaceutical distribution and services company, said Oct. 21, 2026, that it has signed a definitive agreement to acquire American Oncology Network Inc., a physician-led network of more than 350 oncology providers across 21 states, in a transaction that values the group at an enterprise value of $2.4 billion. The deal is Cencora's second large move into community oncology in less than a year, following its majority purchase of OneOncology, and extends the company's push from drug wholesaling into the management of specialty physician practices.
Key developments
- Cencora agreed to acquire all equity interests in American Oncology Network (OTCQX: AONC) that it does not already own; it currently holds about 4% of the company.
- The $2.4 billion enterprise value consists of $2.3 billion payable at closing and contingent value rights of up to $100 million, payable by Cencora if certain conditions are met.
- Certain AON stockholders may roll over equity representing up to 25% of AON; in that case, Cencora expects to pay about $1.7 billion to raise its ownership to 75%.
- Cencora expects the deal to add to adjusted diluted earnings per share in the second year after closing. Closing requires regulatory clearances and AON stockholder approval, and no target date was given.
- Alongside the announcement, Cencora said it now expects fiscal 2026 adjusted diluted EPS of at least $17.90, the high end of its prior $17.75 to $17.95 range.
Industry background
American Oncology Network was founded in 2018 as an alliance of physicians and health care leaders focused on community oncology and related specialties. It provides physician-led care models, value-based care programs, ancillary services and practice management support to independent practices. AON Chief Executive Todd Schonherz said in the announcement that Cencora has been an investor in the network since 2020, and both companies stressed that clinical decisions will continue to rest with AON's physicians.
The structure reflects a model that has spread quickly across U.S. specialty care: the management services organization, or MSO. Under this approach, a corporate partner handles purchasing, billing, revenue cycle work, data and administrative functions, while affiliated physicians keep control of treatment decisions. Cencora President and CEO Robert P. Mauch said the transaction will expand the company's physician-led oncology MSO and strengthen its support for independent practices.
Cencora has been building that platform for several years. In December 2025 it agreed to buy the majority of the OneOncology equity it did not already own from TPG and other shareholders, for about $5.0 billion in cash, and it reported the deal completed in its fiscal first-quarter results released in February 2026. Its December release also described Retina Consultants of America as a recent acquisition, giving Cencora specialty MSO assets in both oncology and ophthalmology.
Industry implications
Oncology is one of the most drug-intensive areas of outpatient medicine. Community practices buy and administer infused and injected cancer therapies in their own clinics, which makes them significant customers for specialty distributors. By owning the MSOs that support those practices, a distributor gains a closer view of purchasing patterns, clinical workflows and the adoption of new therapies, and it can bundle distribution with practice services, data and research support.
For independent oncologists, the deal is part of a wider trade-off. Affiliation with a well-funded partner can provide capital for new sites, technology, specialty pharmacy and ancillary services, and help with value-based payment programs that require scale and analytics. It also ties practices more closely to a single corporate partner. The companies' emphasis on physician control of clinical decisions speaks directly to that concern, and it is likely to be a point of attention for physicians and regulators reviewing the transaction.
Competitive and supply chain implications
The agreement deepens the competition among the three large U.S. drug wholesalers to secure specialty provider networks. McKesson has long supported community oncology through The US Oncology Network, and Cardinal Health has also invested in specialty practice platforms. With OneOncology and AON, Cencora would control two separate oncology networks, which may give it more leverage with drug manufacturers seeking access to community cancer care, including support for clinical trials and real-world evidence programs.
On the supply side, the deal could shift purchasing and distribution relationships at AON-affiliated practices toward Cencora over time, although the companies did not describe any changes to existing supplier arrangements. For drugmakers, a larger and more integrated Cencora oncology footprint means a single partner able to handle distribution, practice-level data and trial site access across a broad community setting. Group purchasing organizations and smaller specialty distributors could face more pressure as wholesalers bring practice networks in-house.
Regional implications
The transaction is focused on the United States. AON's providers practice in 21 states, and many community oncology practices serve suburban and rural areas where patients would otherwise travel to hospital-based cancer centers for infusions and other treatment. Continued investment in these practices could help sustain local access to care, provided the new ownership keeps community sites open and staffed.
Regulatory review will also play out at the federal and state level. The companies said closing requires regulatory clearances, and a growing number of states have adopted or considered rules on notice and review of health care transactions involving physician groups and private investors. How regulators treat a wholesaler acquiring a second oncology network will be watched closely by other consolidators in specialty care.
Credence Research analysis
The AON deal confirms that Cencora's growth strategy is shifting from moving medicines to managing the sites where specialty medicines are prescribed and administered. A second oncology network, added soon after OneOncology closed, signals that management sees practice services as a durable source of earnings and as a way to deepen relationships with pharmaceutical manufacturers. The staged structure, with a possible 75% stake and contingent payments, also lets Cencora keep physician stockholders invested in the outcome, a pattern used across specialty MSO deals.
Execution risk sits in integration and physician retention. Running two oncology MSOs side by side will test whether Cencora can standardize purchasing, data and back-office systems without weakening the local identity of each network. The commitment that clinical decisions remain with physicians will need to hold up in practice, since physician turnover would undermine the value of the platform. Regulatory scrutiny of vertical integration in health care is a further variable, as the combination places a major distributor even closer to prescribing decisions.
What comes next
- AON stockholders must vote on the agreement, which AON's board approved on the unanimous recommendation of a special committee of independent directors.
- Required regulatory clearances must be obtained before closing; the companies have not set a closing date.
- AON stockholders who qualify will decide whether to take part in the equity rollover of up to 25%, which determines Cencora's final ownership level.
- Cencora will report fiscal fourth-quarter 2026 results and discuss its fiscal 2027 outlook on Nov. 4, 2026.
- Integration plans for AON alongside OneOncology are expected to emerge after closing.
Sources
- Cencora press release on American Oncology Network acquisition, SEC Form 8-K Exhibit 99.1 (Oct. 21, 2026)
- American Oncology Network: Cencora to Acquire American Oncology Network (Oct. 21, 2026)
- Cencora press release on OneOncology agreement, SEC Form 8-K Exhibit 99.1 (Dec. 15, 2025)
- Cencora fiscal 2026 first-quarter results, SEC Form 8-K Exhibit 99.1 (Feb. 4, 2026)
Image: A patient receives an intravenous chemotherapy infusion, by Linda Bartlett for the National Cancer Institute via Wikimedia Commons, public domain. Cropped and edited by Credence Research.
About the Author
Senior News Editor at Credence Research Inc